Photo, Julia Braun LL.M.

Julia Braun LL.M.

Baker McKenzie Rechtsanwaltsgesellschaft mbH von Rechtsanwälten und Steuerberatern


Julia Braun joined Baker McKenzie in January 2018 as a member of the Firm's Corporate/M&A group in the Munich office. Julia has 15 years of professional experience in cross-border and domestic M&A, private equity, growth capital, venture capital and other corporate finance transactions. Her experience includes working with biotech and life science companies and their financial sponsors. Julia served as member of her previous law firm's pro bono committee for 10 years. Julia's private equity/venture capital expertise has recently been recognized by Legal 500 and Juve.

Practice Focus

Julia focuses her practice on cross-border and domestic corporate M&A, private equity, growth capital and venture capital transactions, with a particular industry focus on healthcare & life sciences. She advises national and international financial investors, private equity funds, strategic clients and family offices in a broad range of corporate transactions, including private equity and venture capital investments, management buy-outs, co-investment schemes, executive compensation, and divestitures including trade sales.

Representative Legal Matters

  • Advised Allecra Therapeutics on its cross-border licensing of its key compound to Shanghai Haini / Yangtze River Pharmaceutical. Under the terms of the agreement, Allecra will receive payments and milestone fees in an amount of around USD 80 million.

  • Advised CatalYm, a German biotech company developing novel cancer immunotherapies, on the closing of its EUR 50 million Series B equity financing. The financing consortium led by Vesalius Biocapital III includes Novartis Venture Fund (NVF), Wachstumsfonds Bayern, coparion and the founding investors Forbion and BioGeneration Ventures.

  • Advised the German biotech company MODAG on the in-licensing of an innovative substance portfolio (SERY 433) from Max Planck Innovation GmbH to combat neurodegenerative diseases and on the closing of a EUR 12 million Series A financing round, led by the Massa Investment AG, Switzerland.

  • Advised LSP as lead investor in DNA Script on the oversubscribed Series B fundraising of USD 38.5 million for accelerated product development and commercial operations in the US of DNA Script.

  • Advised Hitachi Chemical Company, Ltd., a leading manufacturer of functional materials and advanced components with a strong portfolio in the life sciences industry, on the takeover of German apceth Biopharma, a contract development and manufacturing organization for complex cell-based regenerative gene therapy products.

  • Advised Forbion Capital Partners as lead investor on a EUR 17 million Series C financing of Omeicos Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin.

Prior to joining Baker McKenzie, Julia handled the following matters:

  • Advised a selling investors consortium including Boehringer Ingelheim, Forbion, MP Healthcare, Sunstone Capital and Wellington Partners in an auctioned cross border acquisition of German Rigontec, a leader in RIG-I targeting RNA therapeutics by Merck Sharp Dohme.

  • Advised as investor counsel the lead investor LSP Life Sciences Partners on all legal aspects of Cardior Pharmaceuticals’ Series A Financing, a university carve-out including equity financing, in-licensing of intellectual property from Medizinische Hochschule Hannover and Max Planck Gesellschaft as well as hiring of key personnel.
  • Advised a sellers' consortium led by HeidelbergCapital and Creathor Venture on the sale of their shares in Accovion, a leading European full-service CRO headquartered in Frankfurt to Clinipace Worldwide Inc.

  • Advised NORMA Group AG on its EUR 386 million initial public offering on the Frankfurt Stock Exchange (DACH deal of the year award at the 2012 Real Deals Private Equity Awards for 3i’s successful investment in NORMA).


  • Germany (2006)


  • University of Cape Town (LLM) (2005)
  • Higher Regional Court of Dusseldorf (Second State Exam) (2004)
  • University of Bayreuth (First State Exam) (2001)


  • English
  • German


Author "Virtuelle Beteiligungsprogramme und ihre Behandlung im Exit. Eckpunkte der Ausgestaltung und Abwicklung", Biotechnologie 03-2019, S. 118-119


Merger Control - Transaction Value Thresholds, Killer Acquisitions, Licensing Deals and other Developments 
21.11.2019, Zürich 
15th Annual Baker McKenzie Healthcare Industry Legal and Compliance Forum

Firm Committee Memberships

  • D&I Committee